What are the precautions for Deferasirox?

It is used for synthesis of Deferasirox. The chemical name of deferasirox is 4 - [3,5-bis (2-hydroxyphenyl) - 1,2,4-triazol-1-yl] benzoic acid. It is an iron chelating agent product researched and developed by Novartis Pharmaceuticals, Switzerland. It is the first oral iron repellent approved by the US FDA that can be used routinely. It is approved to be used in patients ≥ 2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a first-line drug for iron overload patients with thalassemia above 6 years old, Clinical research is currently under way in China; Phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerance, and can significantly reduce the iron load of the heart and liver, which is easy to be accepted by patients. At the same time, it also has the pharmacological properties of antifungal (such as Mucor growing in an iron rich environment), anti cell proliferation, anti malaria, anti oxidative stress injury, and anti cytotoxic induced apoptosis; It can be used for the treatment of secondary hemochromatosis, delayed porphyria cutis and other diseases.
　　Deferasirox is an oral iron chelator that was first approved in the United States in 2005. Deferasirox has been shown to reduce iron load in many different types of transfusion-dependent patients, and related studies have confirmed that deferasirox significantly improves hematology, liver function and reduces the incidence of fungal disease. In addition, due to its relatively long plasma half-life (8-16 hours), it only needs to be administered once daily, which greatly increases patient compliance. However, fewer studies have been reported on the role of Deferasirox in improving survival, promoting immune reconstitution, and reducing complications in post-transplant patients, and the few reports have focused on patients with malignant hematologic diseases.
　　Deferasirox should be taken on an empty stomach at least 30 minutes before a meal, once a day, preferably at the same time each day. The tablet should not be chewed or swallowed whole. Deferasirox should not be taken with acid preparations containing aluminum. The administered dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet.
　　Deferasirox Precautions.
　　Patients treated with Deferasirox may develop a rash that usually resolves spontaneously and therefore does not require dose adjustment or discontinuation; however, if the rash is severe or persistent, the patient should discontinue the drug and seek immediate medical attention.
　　Patients should not be treated with Deferasirox if they are allergic to any of its components.
　　Deferasirox has been shown to cause hearing loss and eye problems only in rare cases. Therefore, patients should have a complete hearing and eye examination before receiving this drug and annually thereafter.